06:47 AM EST, 12/19/2024 (MT Newswires) -- Prothena ( PRTA ) said Thursday the phase 2b study conducted by partner Roche evaluating prasinezumab for the treatment of early-stage Parkinson's disease missed its primary endpoint.

However, the study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints, the company said.

The results will therefore be used to inform future clinical development of the drug candidate as a potential disease-modifying treatment for patients with Parkinson's disease.

Meanwhile, Roche is further evaluating the data and will work with health authorities to determine the next steps.

Prothena's ( PRTA ) share price fell over 6% in recent premarket activity Thursday.

Price: 11.21, Change: -0.74, Percent Change: -6.19